

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05425 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/00**

(21) International Application Number: **PCT/EP00/06540**

(22) International Filing Date: **10 July 2000 (10.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**9917012.8 20 July 1999 (20.07.1999) GB**

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GERONI, Cristina [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). RIPA-MONTI, Marina [IT/IT]; Viale Fulvio Testi, 91, I-20162 Milan (IT). CARUSO, Michele [IT/IT]; Via Desiderio, 3, I-20131 Milan (IT). SUARATO, Antonino [IT/IT]; Via degli Imbriani, 39, I-20100 Milano (IT).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *Without international search report and to be republished upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/05425 A2**



(54) Title: **COMBINED PREPARATIONS COMPRISING ANTITUMOR AGENTS**

(57) Abstract: There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and a recombinant humanized anti-HER2 antibody, preferably trastuzumab, in the treatment of tumors and the use of said combination in the treatment and/or prevention of tumor metastasis.

**Title: "Combined preparations comprising antitumor agents"**

The present invention pertains to the field of neoplastic disease therapy. Particularly, this invention provides an antitumor composition comprising an alkylating anthracycline and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal antibody (rhuMab) anti-HER2, trastuzumab (Herceptin<sup>TM</sup>), having a synergistic or additive antineoplastic effect.

- 10 The present invention provides, in a first aspect, a pharmaceutical composition for use in antineoplastic therapy in mammals, including humans, comprising
- an alkylating anthracycline of formula Ia or Ib



- a recombinant humanized anti-HER2 antibody and a pharmaceutically acceptable carrier or excipient.

The recombinant humanized anti-HER2 antibody is preferably, the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

The chemical names of the alkylating anthracyclines of formula Ia and Ib are 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin (Ia) and 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin (Ib). These alkylating anthracyclines were described in Anticancer Drug Design (1995), vol. 10, 641-653, and claimed respectively in US-A-5,532,218 and US-A-5,496,800. Both compounds intercalate

into DNA via the chromophore and alkylate guanine at N<sup>7</sup> position in DNA minor groove via their reactive moiety on position 3' of the amino sugar. Compounds Ia and Ib are able to circumvent the resistance to all major classes of cytotoxics, indicating that the compounds represent a new class of cytotoxic antitumor drugs.

The recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin<sup>TM</sup>) is described in various scientific publications, for example Cancer Res., 1998, 58:2825-2831.

10 The present invention also provides a product comprising an alkylating anthracycline of formula Ia or Ib as defined above and a recombinant humanized anti-HER2 antibody, preferably the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, as combined preparation for simultaneous, separate or sequential use in antitumor therapy.

A further aspect of the present invention is to provide a method of treating a mammal, including a human, suffering from a neoplastic disease comprising administering to said mammal an alkylating anthracycline of formula Ia or Ib as defined above and a recombinant humanized anti-HER2 antibody, preferably the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, in amounts effective to produce a synergistic antineoplastic effect.

A still further aspect of the present invention is to provide a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal, including a human, in need thereof, the method comprising administering to said mammal a combined preparation comprising an alkylating anthracycline of formula Ia or Ib as defined above, and a recombinant humanized anti-HER2 antibody, preferably the the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, in amounts effective to produce a synergistic antineoplastic effect.

By the term "a synergistic antineoplastic effect" as used herein is meant the inhibition of the growth tumor, preferably

the complete regression of the tumor, administering an effective amount of the combination of an alkylating anthracycline of formula Ia or Ib as defined above and a recombinant humanized anti-HER2 antibody to mammals, including humans.

By the term "administered" or "administering" as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration. By "parenteral" is meant intravenous, subcutaneous and intramuscular administration. Oral administration includes administering the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like. Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, intravenous or intramuscular injections.

The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the alkylating anthracycline of formula Ia or Ib as defined above being utilized, the particular pharmaceutical formulation of the recombinant humanized anti-HER2 antibody being utilized, the particular cancer being treated, and the particular patient being treated.

The dosage ranges for the administration of the combined preparation may vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art.

The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.

In the method of the subject invention, the alkylating anthracycline may be administered simultaneously with the

recombinant humanized anti-HER2 antibody, or the compounds may be administered sequentially, in either order.

In the method of the subject invention, for the administration of the alkylating anthracycline of formula Ia or Ib as defined  
5 above, the course of therapy generally employed is from about 0.1 to about 200 mg/m<sup>2</sup> of body surface area. More preferably, the course therapy employed is from about 1 to about 50 mg/m<sup>2</sup> of body surface area.

In the method of the subject invention, for the administration  
10 of the recombinant humanized anti-HER2 antibody, for example for the administration of the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, the course of therapy generally employed is from about 1 to about 1000 mg/m<sup>2</sup> of body surface area. More preferably, the course therapy employed is  
15 from about 50 to about 500 mg/m<sup>2</sup> of body surface area.

The antineoplastic therapy of the present invention is, in particular, suitable for treating breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans. More in particular, the  
20 combined use of an alkylating anthracycline according to the invention and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the HER2 protein, for  
25 example, for patient with metastatic breast cancer over-expressing the HER2 protein.

The antineoplastic therapy according to this invention also comprises the prevention and/or treatment of tumor metastasis. A still further aspect of the present invention is the use of  
30 an alkylating anthracycline of formula Ia or Ib as defined above and a recombinant humanized anti-HER2 antibody, preferably the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, for the treatment of tumors by angiogenesis inhibition.

As stated above, the effectiveness of an alkylating anthracycline of formula Ia or Ib and a recombinant humanized anti-HER2 antibody is significantly increased without a parallel increased toxicity. In other words, the combined  
5 therapy of the present invention enhances the antitumoral effects of the alkylating anthracycline of formula Ia or Ib as defined above and of a recombinant humanized anti-HER2 antibody and thus yields the most effective and least toxic treatment for tumors.


10 The synergistic action displayed by the combined preparations according to the present invention can be shown, for instance, by testing the activity of the combination in mice bearing human tumor xenografts overexpressing HER2 protein, following, for example, the method described in Cancer Research, 1998,  
15 58:2825-2831.

Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.

**CLAIMS**

1. Products containing an alkylating anthracycline of formula Ia or Ib:

5



and a recombinant humanized anti-HER2 antibody as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.

10

2. Products according to claim 1, wherein the recombinant humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

15 3. Products according to claim 1 or 2, wherein the alkylating anthracycline is 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin.

20 4. Products according to any one of claims 1 to 3, wherein the antitumor therapy is for treating cancers over-expressing HER2 protein.

25 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient, an alkylating anthracycline of formula Ia or Ib as defined in claim 1 and a recombinant humanized anti-HER2 antibody.



6. A pharmaceutical composition according to claim 5 wherein the recombinant humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

5

7. Use of an alkylating anthracycline of formula Ia or Ib as defined in claim 1 and a recombinant humanized anti-HER2 antibody in the preparation of a medicament for use in the treatment of tumors, wherein the alkylating anthracycline and the recombinant humanized anti-HER2 antibody are administered simultaneously, separately or sequentially.

8. Use according to claim 7 wherein the recombinant humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

9. Use of an alkylating anthracycline of formula Ia or Ib as defined in claim 1 and a recombinant humanized anti-HER2 antibody in the preparation of a medicament for use in the prevention and/or treatment of tumor metastasis, wherein the alkylating anthracycline and the recombinant humanized anti-HER2 antibody are administered simultaneously, separately or sequentially.

10. Use according to claim 9 wherein the recombinant humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

11. A method of treating a mammal, including a human, suffering from a neoplastic disease comprising administering to said mammal an alkylating anthracycline of formula Ia or Ib as defined above and a recombinant humanized anti-HER2 antibody, in amounts effective to produce a synergistic antineoplastic effect.

12. A method according to claim 11, wherein the recombinant humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

5 13. A method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal, including a human, in need thereof, the method comprising administering to said mammal a combined preparation comprising an alkylating anthracycline of formula Ia or Ib as  
10 defined above, and a recombinant humanized anti-HER2 antibody, in amounts effective to produce a synergistic antineoplastic effect.

14. A method according to claim 13, wherein the recombinant  
15 humanized anti-HER2 antibody is the recombinant humanized monoclonal antibody anti-HER2 trastuzumab.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05425 A3**

(51) International Patent Classification<sup>7</sup>: A61K 31/70,  
39/395, A61P 35/00

(21) International Application Number: PCT/EP00/06540

(22) International Filing Date: 10 July 2000 (10.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9917012.8 20 July 1999 (20.07.1999) GB

(71) Applicant (*for all designated States except US*): PHAR-  
MACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2,  
I-20152 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GERONI, Cristina  
[IT/IT]; Via Correggio, 48, I-20149 Milan (IT). RIPA-  
MONTI, Marina [IT/IT]; Viale Fulvio Testi, 91, I-20162  
Milan (IT). CARUSO, Michele [IT/IT]; Via Desiderio, 3,  
I-20131 Milan (IT). SUARATO, Antonino [IT/IT]; Via  
degli Imbriani, 39, I-20100 Milano (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:  
17 May 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINED PREPARATIONS COMPRISING DAUNORUBICIN DERIVATIVES AND HER2 ANTIBODIES

(57) Abstract: There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridiny-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and a recombinant humanized anti-HER2 antibody, preferably trastuzumab, in the treatment of tumors and the use of said combination in the treatment and/or prevention of tumor metastasis.

WO 01/05425 A3



# INTERNATIONAL SEARCH REPORT

Intern 1al Application No

PCT/EP 00/06540

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/70 A61K39/395 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BASELGA J ET AL: "HER2 Overexpression and Paclitaxel sensitivity in breast cancer: Therapeutic implications" ONCOLOGY,CH,S. KARGER AG, BASEL, vol. 11, no. 3, SUPPL. 02, March 1997 (1997-03), pages 43-48, XP002100077 ISSN: 0030-2414 abstract page 46, column 2, paragraph 4 -page 47, column 1	1-14
Y	US 5 677 171 A (SHEPARD H MICHAEL ET AL) 14 October 1997 (1997-10-14) claims 18,19,37,39 --- -/--	1-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

20 December 2000

Date of mailing of the international search report

29/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

## INTERNATIONAL SEARCH REPORT

Intern 1st Application No

PCT/EP 00/06540

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 705 157 A (GREENE MARK I) 6 January 1998 (1998-01-06) claims 2,5 ---	1-14
E	WO 00 69460 A (GENENTECH INC) 23 November 2000 (2000-11-23) abstract page 11, line 20-23; claims 2,3,7 ---	1-14
X	WO 99 31140 A (GENENTECH INC) 24 June 1999 (1999-06-24) page 12, line 4-6; claims 1,4 abstract ---	1-14
E	WO 00 44225 A (DANNENBERG ANDREW J ; CORNELL RES FOUNDATION INC (US); SUBBARAMAIAH) 3 August 2000 (2000-08-03) page 21 -page 22; claims 2,3,5 ---	1-14
E	WO 00 61185 A (BELLET ROBERT E ; VOGEL CHARLES L (US)) 19 October 2000 (2000-10-19) claims 1,3 ---	1-14
Y	WO 89 06692 A (GENENTECH INC) 27 July 1989 (1989-07-27) page 11, line 12-25; claims 23,28,32 page 12, line 33-35 ---	1-14
Y	EP 0 328 147 A (BRISTOL MYERS CO) 16 August 1989 (1989-08-16) page 8 -page 9; claims 5,11-13,24,26 -----	1-14

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. Application No

PCT/EP 00/06540

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5677171 A	14-10-1997	US 5772997 A	30-06-1998
		US 5770195 A	23-06-1998
		US 5720954 A	24-02-1998
		JP 11335297 A	07-12-1999
		JP 11255666 A	21-09-1999
		JP 3502885 T	04-07-1991
		WO 8906692 A	27-07-1989
		US 5720937 A	24-02-1998
		US 5725856 A	10-03-1998
US 5705157 A	06-01-1998	NONE	
WO 0069460 A	23-11-2000	NONE	
WO 9931140 A	24-06-1999	AU 1908199 A	05-07-1999
		EP 1037926 A	27-09-2000
		NO 20002957 A	11-08-2000
WO 0044225 A	03-08-2000	NONE	
WO 0061185 A	19-10-2000	NONE	
WO 8906692 A	27-07-1989	JP 11335297 A	07-12-1999
		JP 11255666 A	21-09-1999
		JP 3502885 T	04-07-1991
		US 5677171 A	14-10-1997
		US 5720937 A	24-02-1998
		US 5772997 A	30-06-1998
		US 5725856 A	10-03-1998
		US 5770195 A	23-06-1998
		US 5720954 A	24-02-1998
EP 0328147 A	16-08-1989	AT 105486 T	15-05-1994
		CA 2010164 A	15-08-1991
		DE 68915179 D	16-06-1994
		DE 68915179 T	06-10-1994
		DK 63989 A	12-08-1989
		ES 2053828 T	01-08-1994
		FI 890599 A	12-08-1989
		IE 64650 B	23-08-1995
		IL 89220 A	27-02-1994
		IL 106992 A	24-06-1994
		JP 1246295 A	02-10-1989
		JP 2740841 B	15-04-1998
		KR 9615398 B	13-11-1996
		NO 178229 B	06-11-1995
		NO 950099 A	14-08-1989
		NZ 227911 A	27-11-1990
		PT 89683 A, B	04-10-1989
		US 5122368 A	16-06-1992
		ZA 8900938 A	29-11-1989